We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Technologies (A - Free Report) reported third-quarter fiscal 2022 earnings of $1.34 per share, beating the Zacks Consensus Estimate by 11.7%. The bottom line increased 21.8% year over year and 18.6% sequentially.
Revenues of $1.72 billion surpassed the Zacks Consensus Estimate by 4.9%. The top line was up 8% on a reported basis and 13% on a core basis from the respective year-ago quarter’s levels. Revenues increased 6.9% from the prior quarter’s figure.
Top-line growth was driven by continued strong growth in the pharma market. Also, solid momentum in the chemical & energy market remained positive.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent has three reporting segments, namely Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
LSAG: The segment accounted for $1.02 billion or 59% of its total revenues, up 14% on a reported basis and 18% on a core basis from the respective prior-year quarter’s levels. This was driven by a positive environment across the Pharma, Chemical & Energy, Food, and Environmental & Forensics markets. Growth in LC & LC-MS instruments and Spectroscopy, Consumables and Chemistries, and Cell Analysis platforms also aided results.
ACG: Revenues from the segment were $359 million, accounting for 21% of total revenues. Also, the top line improved 5% year over year on a reported basis and 10% on a core basis, driven by growth in instrument sales. Strong performance of lab activity in China also drove the segment’s results.
DGG: Revenues decreased 2% year over year on a reported basis but rose 3% on a core basis to $340 million, accounting for the remaining 20% of total revenues. The metric was negatively impacted by the shutdown of NASD facility. Nevertheless, strong performance across clinical cancer testing and NGS businesses benefited the results.
Operating Results
For the fiscal third quarter, gross margin in the LSAG segment expanded 10 basis points (bps) on a year-over-year basis to 60.5%. DGG’s gross margin expanded 50 bps on a year-over-year basis to 54%. ACG gross margin expanded 40 bps to 47%.
Research & development costs were $116 million, up 2.7% year over year. Selling, general & administrative expenses were $412 million, up 2.2% year over year.
Operating margin for the fiscal third quarter was 27.5%, expanding 150 bps on a year-over-year basis.
Segment wise, the operating margin for LSAG was up 260 bps year over year to 30.5%. The DGG segment’s operating margin contracted 110 bps on a year-over-year basis to 21.5%. ACG’s operating margin was 24.6%, which expanded 20 bps from the year-ago quarter’s level.
Balance Sheet
As of Jul 31, 2022, Agilent’s cash and cash equivalents were $1.07 billion, down from $1.19 billion on Apr 30, 2022.
Accounts receivables were $1.35 billion at the end of third-quarter fiscal 2022, up from $1.24 billion at the end of second-quarter fiscal 2022.
Long-term debt was $2.732 billion for the reported quarter, up from $2.730 billion in the prior quarter.
Outlook
For the fiscal fourth quarter, management expects revenues of $1.750-$1.775 billion, suggesting growth between 10.3% and 11.8% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for revenues stands at $1.77 billion.
Non-GAAP earnings per share are expected to be $1.38-1.40. The Zacks Consensus Estimate for earnings is pegged at $1.35 per share.
For fiscal 2022, management anticipates revenues in the band of $6.750-$6.775 billion, implying growth of 6.8-7.2% on a reported basis and 9.9-10.3% on a core basis from the respective fiscal 2021 tallies. The Zacks Consensus Estimate for full-fiscal revenues is pegged at $6.69 billion.
Management raised its guidance for non-GAAP earnings per share from $4.86-$4.93 to $5.06-$5.08. The Zacks Consensus Estimate for earnings is pegged at $4.88 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #4 (Sell).
Investors interested in the broader Zacks Computer & Technology sector can consider some better-ranked stocks like Arista Networks (ANET - Free Report) ,Keysight Technologies (KEYS - Free Report) and ASE Technology (ASX - Free Report) . While Arista Networks sports a Zacks Rank #1 (Strong Buy), Keysight Technologies and ASE Technology carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks has lost 9.6% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 18.9%.
Keysight Technologies has lost 17.4% in the year-to-date period. KEYS’ long-term earnings growth rate is currently projected at 9.1%.
ASE technology has lost 19.2% in the year-to-date period. The long-term earnings growth rate for ASX is currently projected at 23.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agilent (A) Q3 Earnings Surpass Estimates, Revenues Rise Y/Y
Agilent Technologies (A - Free Report) reported third-quarter fiscal 2022 earnings of $1.34 per share, beating the Zacks Consensus Estimate by 11.7%. The bottom line increased 21.8% year over year and 18.6% sequentially.
Revenues of $1.72 billion surpassed the Zacks Consensus Estimate by 4.9%. The top line was up 8% on a reported basis and 13% on a core basis from the respective year-ago quarter’s levels. Revenues increased 6.9% from the prior quarter’s figure.
Top-line growth was driven by continued strong growth in the pharma market. Also, solid momentum in the chemical & energy market remained positive.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
Segmental Top-Line Details
Agilent has three reporting segments, namely Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
LSAG: The segment accounted for $1.02 billion or 59% of its total revenues, up 14% on a reported basis and 18% on a core basis from the respective prior-year quarter’s levels. This was driven by a positive environment across the Pharma, Chemical & Energy, Food, and Environmental & Forensics markets. Growth in LC & LC-MS instruments and Spectroscopy, Consumables and Chemistries, and Cell Analysis platforms also aided results.
ACG: Revenues from the segment were $359 million, accounting for 21% of total revenues. Also, the top line improved 5% year over year on a reported basis and 10% on a core basis, driven by growth in instrument sales. Strong performance of lab activity in China also drove the segment’s results.
DGG: Revenues decreased 2% year over year on a reported basis but rose 3% on a core basis to $340 million, accounting for the remaining 20% of total revenues. The metric was negatively impacted by the shutdown of NASD facility. Nevertheless, strong performance across clinical cancer testing and NGS businesses benefited the results.
Operating Results
For the fiscal third quarter, gross margin in the LSAG segment expanded 10 basis points (bps) on a year-over-year basis to 60.5%. DGG’s gross margin expanded 50 bps on a year-over-year basis to 54%. ACG gross margin expanded 40 bps to 47%.
Research & development costs were $116 million, up 2.7% year over year. Selling, general & administrative expenses were $412 million, up 2.2% year over year.
Operating margin for the fiscal third quarter was 27.5%, expanding 150 bps on a year-over-year basis.
Segment wise, the operating margin for LSAG was up 260 bps year over year to 30.5%. The DGG segment’s operating margin contracted 110 bps on a year-over-year basis to 21.5%. ACG’s operating margin was 24.6%, which expanded 20 bps from the year-ago quarter’s level.
Balance Sheet
As of Jul 31, 2022, Agilent’s cash and cash equivalents were $1.07 billion, down from $1.19 billion on Apr 30, 2022.
Accounts receivables were $1.35 billion at the end of third-quarter fiscal 2022, up from $1.24 billion at the end of second-quarter fiscal 2022.
Long-term debt was $2.732 billion for the reported quarter, up from $2.730 billion in the prior quarter.
Outlook
For the fiscal fourth quarter, management expects revenues of $1.750-$1.775 billion, suggesting growth between 10.3% and 11.8% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for revenues stands at $1.77 billion.
Non-GAAP earnings per share are expected to be $1.38-1.40. The Zacks Consensus Estimate for earnings is pegged at $1.35 per share.
For fiscal 2022, management anticipates revenues in the band of $6.750-$6.775 billion, implying growth of 6.8-7.2% on a reported basis and 9.9-10.3% on a core basis from the respective fiscal 2021 tallies. The Zacks Consensus Estimate for full-fiscal revenues is pegged at $6.69 billion.
Management raised its guidance for non-GAAP earnings per share from $4.86-$4.93 to $5.06-$5.08. The Zacks Consensus Estimate for earnings is pegged at $4.88 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #4 (Sell).
Investors interested in the broader Zacks Computer & Technology sector can consider some better-ranked stocks like Arista Networks (ANET - Free Report) ,Keysight Technologies (KEYS - Free Report) and ASE Technology (ASX - Free Report) . While Arista Networks sports a Zacks Rank #1 (Strong Buy), Keysight Technologies and ASE Technology carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks has lost 9.6% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 18.9%.
Keysight Technologies has lost 17.4% in the year-to-date period. KEYS’ long-term earnings growth rate is currently projected at 9.1%.
ASE technology has lost 19.2% in the year-to-date period. The long-term earnings growth rate for ASX is currently projected at 23.1%.